Assessing long‐term upgrade risks in recurrent low‐grade non‐muscle‐invasive bladder cancer, can we deintensify the treatment?

This article discusses the treatment of low-grade non-muscle-invasive bladder cancer (NMIBC) and the potential for deintensifying treatment to avoid overtreatment while maintaining oncological safety. The study found that the majority of patients with low-grade NMIBC do not experience progression to high-grade disease, suggesting the potential for treatment de-intensification. Factors such as age were associated with an increased risk of high-grade recurrence. The study highlights the need for personalized follow-up and management for patients with low-grade NMIBC and suggests the use of less invasive approaches in selected patients. However, the study has limitations due to its retrospective design and limited sample size. Further research is needed to confirm these findings and provide more robust evidence. [Extracted from the article]